Conclusion: Comprehensive meta-analysis indicates a higher prevalence and incidence of BM in patients with certain targetable genomic alterations. This supports brain imaging at staging and follow-up, and the need for targeted therapies with brain penetrance.
PubMed 37392903 ↗P21
The short answer. There isn't much data on P21 yet — 75 mentions, 19 with a clear outcome — so treat these numbers as anecdotal. It is most often used for focus: 83% of 12 reports say that improved. It is well studied — 271 meta-analyses on PubMed. It is not an approved supplement and carries real risks.
From 75 mentions in total — the rest didn't say how it went and aren't counted.
What P21 does, according to users
Of the people who reported each effect, the share who said it got better.
4 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 271 meta-analyses on PubMed ↗ · 51 randomized trials ↗
Conclusion: Among the ALL subtypes, positive predictive values of greater than 0.8 were reached only for the L3-associated aberrations t(2;8) (1.0), t(8;14) (0.95), t(8;22) (0.87), and dup(I) (0.80). The highest negative predictive values were in AML 0.98 that the disease is not M3 if t(15;17) is not found, and in ALL 0.96 that the patient does not have L3 if a t(8;14) is not detected.
PubMed 1384663 ↗Conclusion: Mendelian randomisation analysis supports causal roles for several HF risk factors, and demonstrates CAD-independent effects for atrial fibrillation, body mass index, and hypertension. These findings extend our knowledge of the pathways underlying HF and may inform new therapeutic strategies.
PubMed 31919418 ↗Conclusion: This is the first investigation of cancer risk in KRAS or HRAS PV-positive mosaic RASopathies to date. The high incidence and SIR values found highlight the need for rigorous RMS surveillance in young children and skin cancer surveillance in adults with this high-risk condition.
PubMed 39287844 ↗9 human trials on ClinicalTrials.gov test P21 — 6 completed, 1 recruiting now. See all on ClinicalTrials.gov ↗
- KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia · Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse · 2025
- Molecular Pathways Related to Short-term Fasting Response · Fasting · 2016
- Inferior Vena Cava (IVC) Size in Acute Renal Failure · Acute Renal Failure · 2016
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I have been taking 1mg of p21 for about two weeks, and my concentration has improved markedly but my memory has improved even more so.”
“P21 was a strange combination of unpleasant stimulation and lethargy, which had a pretty negative impact on my sleep.”
“I had high hopes for all of these, and all were helpful in their own way, but I can't say I've noticed any long-term benefits from any of them.”
“It had more of an activating feel in my experience. Somewhat anxiogenic at times even.”
Top discussions (5)
- Healing brain after years of sleep deprivation ↗
- I fed this subreddit into a language model to see the most popular + top treatments, the results look pretty good! ↗
- A way to (maybe) prevent neurological diseases like ALS, Alzheimer’s and Parkinson’s ↗
- I recovered from drug-induced cognitive damage with nootropics ↗
- First impressions of testosterone ↗
P21 compared
Other options for focus
Sources
- User reports: 75 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate